tranexamic acid has been researched along with Telangiectasia, Hereditary Hemorrhagic in 24 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Telangiectasia, Hereditary Hemorrhagic: An autosomal dominant vascular anomaly characterized by telangiectases of the skin and mucous membranes and by recurrent gastrointestinal bleeding. This disorder is caused by mutations of a gene (on chromosome 9q3) which encodes endoglin, a membrane glycoprotein that binds TRANSFORMING GROWTH FACTOR BETA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid reduces epistaxis in patients with hereditary hemorrhagic telangiectasia." | 9.19 | Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. ( Bieg, B; Geisthoff, UW; König, J; Kübler, M; Plinkert, PK; Seyfert, UT, 2014) |
| "Although intravascular thrombi and infarct-type necrosis have been reported in leiomyomas following tranexamic acid therapy, intratumoral vasculopathy resembling acute atherosis has not been reported to date in patients without exposure to gonadotropin receptor agonist." | 7.85 | Intratumoral Vasculopathy in Leiomyoma Treated With Tranexamic Acid. ( Krigman, HR; Kudose, S, 2017) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 6.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "Hereditary hemorrhagic telangiectasia has been underreported for many years." | 5.38 | Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. ( Collins, C; Flanagan, BA; Parra, S, 2012) |
| "Among patients with HHT, there were no significant between-group differences in the use of topical intranasal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency." | 5.22 | Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. ( Chakinala, MM; Clancy, MS; Everett, EM; Faughnan, ME; Gossage, JR; James, M; Johnson, MH; McWilliams, JP; Merlo, CA; Oh, SP; Olitsky, SE; Pyeritz, RE; Sautter, NB; Whitehead, KJ, 2016) |
| "Tranexamic acid reduces epistaxis in patients with hereditary hemorrhagic telangiectasia." | 5.19 | Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. ( Bieg, B; Geisthoff, UW; König, J; Kübler, M; Plinkert, PK; Seyfert, UT, 2014) |
| " In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion." | 4.98 | Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. ( Clark, C; Halderman, AA; Invernizzi, R; Marple, BF; Poetker, DM; Reh, DD; Ryan, MW; Sindwani, R, 2018) |
| "Although intravascular thrombi and infarct-type necrosis have been reported in leiomyomas following tranexamic acid therapy, intratumoral vasculopathy resembling acute atherosis has not been reported to date in patients without exposure to gonadotropin receptor agonist." | 3.85 | Intratumoral Vasculopathy in Leiomyoma Treated With Tranexamic Acid. ( Krigman, HR; Kudose, S, 2017) |
| "The anti-fibrinolytic agent tranexamic acid (TXA) has been used to reduce bleeding in patients with hereditary hemorrhagic telangiectasia (HHT); however, there are limited data on its efficacy and safety." | 3.81 | The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey. ( Faughnan, ME; Ravichakaravarthy, T; Shehata, N; Zaffar, N, 2015) |
| "A 3-year prospective study was carried on HHT patients with epistaxis treated with oral tranexamic acid in the HHT unit at our hospital." | 3.74 | [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. ( Botella, LM; Fernández, A; Morales-Angulo, C; Pérez del Molino, A; Sanz-Rodríguez, F; Zarrabeitia, R, 2007) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 2.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "Hereditary hemorrhagic telangiectasia is a rare autosomal dominant inherited disease characterized by vascular dysplasia." | 1.43 | Definite hereditary hemorrhagic telangiectasia in a 60-year-old black Kenyan woman: a case report. ( Bloomfield, GS; Kiyeng, JC; Koech, C; Siika, A, 2016) |
| "Hereditary hemorrhagic telangiectasia has been underreported for many years." | 1.38 | Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. ( Collins, C; Flanagan, BA; Parra, S, 2012) |
| "Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT)." | 1.34 | Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. ( Bernabéu, C; Botella, LM; Fernandez-L, A; Garrido-Martin, EM; Morales-Angulo, C; Perez-Molino, A; Ramirez, JR; Sanz-Rodriguez, F; Zarrabeitia, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimori, S | 1 |
| Al-Samkari, H | 1 |
| Halderman, AA | 1 |
| Ryan, MW | 1 |
| Clark, C | 1 |
| Sindwani, R | 1 |
| Reh, DD | 1 |
| Poetker, DM | 1 |
| Invernizzi, R | 1 |
| Marple, BF | 1 |
| Hsu, YP | 1 |
| Hsu, CW | 1 |
| Bai, CH | 1 |
| Cheng, SW | 1 |
| Chen, C | 1 |
| Lacout, A | 2 |
| Marcy, PY | 2 |
| El Hajjam, M | 2 |
| Lacombe, P | 2 |
| Geisthoff, UW | 1 |
| Seyfert, UT | 1 |
| Kübler, M | 1 |
| Bieg, B | 1 |
| Plinkert, PK | 1 |
| König, J | 1 |
| Gaillard, S | 1 |
| Dupuis-Girod, S | 1 |
| Boutitie, F | 1 |
| Rivière, S | 1 |
| Morinière, S | 1 |
| Hatron, PY | 1 |
| Manfredi, G | 1 |
| Kaminsky, P | 1 |
| Capitaine, AL | 1 |
| Roy, P | 1 |
| Gueyffier, F | 1 |
| Plauchu, H | 1 |
| Zaffar, N | 1 |
| Ravichakaravarthy, T | 1 |
| Faughnan, ME | 2 |
| Shehata, N | 1 |
| Kiyeng, JC | 1 |
| Siika, A | 1 |
| Koech, C | 1 |
| Bloomfield, GS | 1 |
| Whitehead, KJ | 1 |
| Sautter, NB | 1 |
| McWilliams, JP | 1 |
| Chakinala, MM | 1 |
| Merlo, CA | 1 |
| Johnson, MH | 1 |
| James, M | 1 |
| Everett, EM | 1 |
| Clancy, MS | 1 |
| Oh, SP | 1 |
| Olitsky, SE | 1 |
| Pyeritz, RE | 1 |
| Gossage, JR | 1 |
| Kudose, S | 1 |
| Krigman, HR | 1 |
| Robard, L | 1 |
| Michel, J | 1 |
| Prulière Escabasse, V | 1 |
| Bequignon, E | 1 |
| Vérillaud, B | 1 |
| Malard, O | 1 |
| Crampette, L | 1 |
| Ghosh, K | 2 |
| Molinos-Castro, S | 1 |
| Pesqueira-Fontán, PM | 1 |
| Díaz-Peromingo, JA | 1 |
| Flanagan, BA | 1 |
| Collins, C | 1 |
| Parra, S | 1 |
| Pérez del Molino, A | 2 |
| Zarrabeitia, R | 3 |
| Fernández, A | 2 |
| Botella, LM | 3 |
| Pollak, L | 1 |
| Strauss, S | 1 |
| Sanset, S | 1 |
| Peer, A | 1 |
| Tishler, M | 1 |
| Fernandez-L, A | 1 |
| Garrido-Martin, EM | 1 |
| Sanz-Rodriguez, F | 2 |
| Ramirez, JR | 1 |
| Morales-Angulo, C | 2 |
| Perez-Molino, A | 1 |
| Bernabéu, C | 1 |
| Wechalekar, A | 1 |
| Parapia, L | 1 |
| Klepfish, A | 1 |
| Berrebi, A | 1 |
| Schattner, A | 1 |
| Sabbà, C | 1 |
| Gallitelli, M | 1 |
| Palasciano, G | 1 |
| Lozano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia[NCT01031992] | Phase 3 | 23 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.[NCT00355108] | Phase 3 | 170 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Low-dose Sirolimus for Nosebleeds in HHT: A Phase II Pilot Study[NCT05269849] | Phase 2 | 10 participants (Anticipated) | Interventional | 2022-03-16 | Recruiting | ||
| North American Study of Epistaxis in HHT (NOSE)[NCT01408030] | Phase 2 | 123 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department[NCT02930941] | Phase 4 | 35 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Terminate due to slow enrollment rate.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total minutes of bleeding per week (NCT01408030)
Timeframe: 5-12 weeks of active treatment
| Intervention | Total minutes of bleeding per week (Median) |
|---|---|
| Bevacizumab Spray | 23.5 |
| Estriol Spray | 36.5 |
| Tranexamic Acid Spray | 44.5 |
| Placebo Spray | 46 |
Bleeding episodes per week (NCT01408030)
Timeframe: Weeks 5-12 of active treatment phase
| Intervention | Bleeding episodes per week (Median) |
|---|---|
| Bevacizumab Spray | 7.0 |
| Estriol Spray | 8.0 |
| Tranexamic Acid Spray | 7.5 |
| Placebo Spray | 8.0 |
grams/100 ml, assessed at week 12 (NCT01408030)
Timeframe: 12 weeks
| Intervention | gram/100 ml (Median) |
|---|---|
| Bevacizumab Spray | 12.8 |
| Estriol Spray | 13.1 |
| Tranexamic Acid Spray | 11.4 |
| Placebo Spray | 13.8 |
Hoag Epistaxis Severity Score (ESS) is based on 6 nosebleed variables such as frequency and duration which are entered by patients. The ESS has a minimum value of 0 and maximum value of 10, with 10 representing more severe epistaxis. (NCT01408030)
Timeframe: 12 weeks
| Intervention | units on a scale (0-10) (Median) |
|---|---|
| Bevacizumab Spray | 3.54 |
| Estriol Spray | 3.56 |
| Tranexamic Acid Spray | 4.06 |
| Placebo Spray | 3.74 |
Number of participants requiring RBC transfusion during weeks 1-12 (NCT01408030)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab Spray | 1 |
| Estriol Spray | 2 |
| Tranexamic Acid Spray | 5 |
| Placebo Spray | 3 |
Treatment failure is defined as the occurrence of one or more of the following during the study: need for nasal surgery or chemical cautery or other new treatment modality to control epistaxis; transfusion of more than 12 units of RBC; severe complications such as acute myocardial infarction, venous thromboembolism, brain hemorrhage; or death (NCT01408030)
Timeframe: Baseline through 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab Spray | 2 |
| Estriol Spray | 5 |
| Tranexamic Acid Spray | 0 |
| Placebo Spray | 3 |
Length of stay was defined as time from enrollment in study to discharge from the emergency department (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 268 |
| NS Group | 346 |
The number of participants with re-bleeding at 24 Hours was evaluated during follow up phone call (NCT02930941)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 3 |
| NS Group | 9 |
The number of participants with re-bleeding at one week was evaluated during the follow-up phone call (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 2 |
| NS Group | 6 |
Patient reported thromboembolic events during follow-up phone calls at 24 hours and at one week (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 0 |
| NS Group | 0 |
Time to control of bleeding was defined as the time from the start of enrollment and direct pressure and administration of study drug to the resolution of bleeding (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 64 |
| NS Group | 42 |
Patient-reported drug-related adverse events during ED visit (NCT02930941)
Timeframe: during emergency department (ED) visit
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Nasal burning | Nasal irritation | Unpleasant taste | |
| NS Group | 0 | 0 | 0 |
| TXA Group | 2 | 0 | 1 |
6 reviews available for tranexamic acid and Telangiectasia, Hereditary Hemorrhagic
| Article | Year |
|---|---|
Tranexamic acid may be a useful pharmacotherapy for endoscopically resistant small bowel angiodysplasia.
Topics: Angiodysplasia; Colonic Diseases; Gastrointestinal Hemorrhage; Humans; Telangiectasia, Hereditary He | 2023 |
Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care.
Topics: Anemia; Angiogenesis Inhibitors; Anticoagulants; Antifibrinolytic Agents; Clinical Trials as Topic; | 2021 |
Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Epistaxis; Estriol; Estrogen | 2018 |
Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
Topics: Angiogenesis Inhibitors; Bevacizumab; Epistaxis; Female; Humans; Male; Prognosis; Quality of Life; R | 2019 |
Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease.
Topics: Antifibrinolytic Agents; Catheter Ablation; Epistaxis; Hemostatic Techniques; Hemostatics; Humans; L | 2017 |
[Pharmacological treatment of hereditary haemorrhagic telangiectasia].
Topics: Antifibrinolytic Agents; Blood Transfusion; Hormones; Humans; Telangiectasia, Hereditary Hemorrhagic | 2009 |
3 trials available for tranexamic acid and Telangiectasia, Hereditary Hemorrhagic
| Article | Year |
|---|---|
Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Angiogenesis Inhibitors; Antifibri | 2016 |
15 other studies available for tranexamic acid and Telangiectasia, Hereditary Hemorrhagic
| Article | Year |
|---|---|
Tranexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis.
Topics: Antifibrinolytic Agents; Epistaxis; Female; Humans; Telangiectasia, Hereditary Hemorrhagic; Tranexam | 2013 |
The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey.
Topics: Aged; Epistaxis; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Retrospective Studies; Surv | 2015 |
Definite hereditary hemorrhagic telangiectasia in a 60-year-old black Kenyan woman: a case report.
Topics: Antifibrinolytic Agents; Arteriovenous Fistula; Arteriovenous Malformations; Blood Transfusion; Comp | 2016 |
Intratumoral Vasculopathy in Leiomyoma Treated With Tranexamic Acid.
Topics: Female; Humans; Hysterectomy; Leiomyoma; Menorrhagia; Middle Aged; Necrosis; Telangiectasia, Heredit | 2017 |
Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.
Topics: Adult; Antifibrinolytic Agents; Cardiomyopathy, Hypertrophic; Colectomy; Colostomy; Embolization, Th | 2008 |
Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Epistaxis; Female; Humans; Middle Aged; Telangi | 2012 |
Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.
Topics: Antibodies, Monoclonal, Humanized; Arteriovenous Malformations; Bevacizumab; Drug Synergism; Humans; | 2012 |
[Efficacy of tranexamic acid in a patient with hereditary hemorrhagic telangiectasia and massive epistaxis].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Epistaxis; Humans; Male; Telangiectasia, Hereditar | 2004 |
Acute confusion in an elderly woman with Rendu-Osler-Weber disease.
Topics: Acute Disease; Aged; Antifibrinolytic Agents; Confusion; Consciousness Disorders; Delirium; Electroe | 2006 |
Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Adult; Aged; Aged, 80 a | 2007 |
[Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Drug Administration Schedule; Epistaxis; Fe | 2007 |
Hereditary haemorrhagic telangiectasia with protein S deficiency in a family: a case report.
Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Female; Humans; Male; Nuclear Family; Protein | 2000 |
Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Epistaxis; Humans; Male; Middle Aged; Telangiec | 2001 |
Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Topics: Aged; Antifibrinolytic Agents; Epistaxis; Humans; Male; Telangiectasia, Hereditary Hemorrhagic; Tran | 2001 |
Tranexamic acid in hereditary hemorrhagic telangiectasia.
Topics: Antifibrinolytic Agents; Body Weight; Epistaxis; Humans; Telangiectasia, Hereditary Hemorrhagic; Tra | 2002 |